Evidence map›Paper›PMID 27038607›Full record

ArticleDiagnostic pathology2016

Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer.

M Caroline Vos, Anneke A M van der Wurff, Johan Bulten, Roy Kruitwagen, Harrie Feijen, Toin H van Kuppevelt, Thijs Hendriks, Leon F A G Massuger

Open access · goldAbstract readEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

M Caroline VosDepartment of Obstetrics and Gynaecology, Elisabeth Tweesteden Hospital, PO Box 90151, 5000 LC, Tilburg, The Netherlands. c.vos@elisabeth.nl.
Anneke A M van der WurffDepartment of Pathology, Elisabeth Tweesteden Hospital, PO Box 90151, 5000 LC, Tilburg, The Netherlands.
Johan BultenDepartment of Pathology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Roy KruitwagenDepartment of Obstetrics and Gynaecology, Tweesteden Ziekenhuis, PO Box 90107, 5000 LA, Tilburg, The Netherlands.
Harrie FeijenDepartment of Obstetrics and Gynaecology, Amphia Hospital, Langedijk 75, 4819 EV, Breda, The Netherlands.
Toin H van KuppeveltDepartment of Biochemistry, Radboud Insitute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Thijs HendriksDepartment of Surgery, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Leon F A G MassugerDepartment of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Elisabeth-TweeSteden Ziekenhuis · NLRadboud University Nijmegen · NLAmphia Ziekenhuis · NLRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian cancer with data on long-term follow-up.

methodsTumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated. Clinical and survival data were collected and related to known prognostic factors, as well as to the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.

resultsEpithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p < .01) and epithelial MMP-2 expression was found to correlate with both MMP-14 epithelial and stromal expression (rho = -.28, p < .01 respectively rho = -.21, p < .05). In univariable analysis of 64 advanced-staged tumours, no MMP parameter was significant for progression-free or overall survival. In multivariable analysis for PFS, stromal MMP-14 expression and epithelial MMP-2 expression remained in the model. For overall survival, no MMP parameter showed significance.

conclusionsWe confirmed the correlation between epithelial and stromal MMP-14 expression and between epithelial MMP-2 and both epithelial and stromal MMP-14 expression. In this study with long-term follow-up, the independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer is limited to a role in PFS for stromal MMP-14 expression and epithelial MMP-2 expression.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEpithelial CellsFemaleHumansImmunohistochemistryKaplan-Meier EstimateMatrix Metalloproteinase 14Matrix Metalloproteinase 2Middle AgedMultivariate AnalysisNeoplasm StagingNetherlandsBiomarkers, TumorMatrix Metalloproteinase 14Matrix Metalloproteinase 2MMP14 protein, humanMMP2 protein, humanImmunohistochemistryMMP-14MMP-2Ovarian cancerPrognosis

Identifiers

PMID27038607
PMCPMC4818939
OpenAlexW2318391777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.